Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mercadolibre Inc (MELI) vs Twist Bioscience Corp (TWST) Price & Performance

Mercadolibre IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Mercadolibre Inc vs Twist Bioscience Corp — how do they compare? Mercadolibre Inc trades at $1,813.38 (market cap $92.90B), while Twist Bioscience Corp trades at $94.11 (market cap $5.45B). The key difference: Mercadolibre Inc is far larger — about 17× Twist Bioscience Corp's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals.

MELITWST
Market Cap
$92.90B$5.45B
Sector
Consumer CyclicalHealth
52-Week High
$2.51K$102.88
52-Week Low
$1.55K$24.16
Enterprise Value
$99.79B$5.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mercadolibre Inc

MercadoLibre (MELI) trades at $1,832.29, up 1.01% in the last session, while showing a bearish technical signal overall. The company reported strong revenue growth, with 2025 revenue reaching $28.89 billion, though recent quarterly EPS results have missed expectations. Operating cash flow improved significantly to $12.12 billion in 2025, and analyst sentiment remains strongly positive with a consensus price target of $2,230.

The outlook for MELI is supported by robust top-line expansion and strategic investments in logistics and fintech, but near-term margin pressure and recent earnings misses present risks. The stock offers growth potential in Latin American e-commerce and digital payments, balanced by competitive and execution challenges in a dynamic market environment.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.

The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mercadolibre Inc

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

Read more on MELI

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST